Cite
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts
MLA
Sharmin, Sifat, et al. “Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts.” Sharmin , S , Lefort , M , Andersen , J B , Leray , E , Horakova , D , Havrdova , E K , Alroughani , R , Izquierdo , G , Ozakbas , S , Patti , F , Onofrj , M , Lugaresi , A , Terzi , M , Grammond , P , Grand’Maison , F , Yamout , B , Prat , A , Girard , M , Duquette , P , Boz , C , Trojano , M , McCombe , P , Slee , M , Lechner-Scott , J , Turkoglu , R , Sola , P , Ferraro , D , Granella , F , Prevost , J , Maimone , D , Skibina , O , Buzzard , K , Van Der Walt , A , Van Wijmeersch , B , Csepany , T , Spitaleri , D , Vucic , S , Casey , R , Debouverie , M , Edan , G , Ciron , J , Ruet , A , Sellebjerg , F T , Soerensen , P S , Jensen , M B , Frederiksen , J L , Bramow , S , Mathiesen , H K , Schreiber , K I , Magyari , M & Danish Multiple Sclerosis Registry, OFSEP and the MSBase Investigators 2021 , ’ Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ’ , CNS Drugs , Vol. 35 , Pp. 1217–1232 , 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1322766594&authtype=sso&custid=ns315887.
APA
Sharmin, S., Lefort, M., Andersen, J. B., Leray, E., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand, M. F., Yamout, B., Prat, A., Girard, M., Duquette, P., … Magyari, M. (2021). Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts. Sharmin , S , Lefort , M , Andersen , J B , Leray , E , Horakova , D , Havrdova , E K , Alroughani , R , Izquierdo , G , Ozakbas , S , Patti , F , Onofrj , M , Lugaresi , A , Terzi , M , Grammond , P , Grand’Maison , F , Yamout , B , Prat , A , Girard , M , Duquette , P , Boz , C , Trojano , M , McCombe , P , Slee , M , Lechner-Scott , J , Turkoglu , R , Sola , P , Ferraro , D , Granella , F , Prevost , J , Maimone , D , Skibina , O , Buzzard , K , Van Der Walt , A , Van Wijmeersch , B , Csepany , T , Spitaleri , D , Vucic , S , Casey , R , Debouverie , M , Edan , G , Ciron , J , Ruet , A , Sellebjerg , F T , Soerensen , P S , Jensen , M B , Frederiksen , J L , Bramow , S , Mathiesen , H K , Schreiber , K I , Magyari , M & Danish Multiple Sclerosis Registry, OFSEP and the MSBase Investigators 2021 , ’ Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ’ , CNS Drugs , Vol. 35 , Pp. 1217–1232 .
Chicago
Sharmin, Sifat, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Eva Kubala Havrdova, Raed Alroughani, et al. 2021. “Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts.” Sharmin , S , Lefort , M , Andersen , J B , Leray , E , Horakova , D , Havrdova , E K , Alroughani , R , Izquierdo , G , Ozakbas , S , Patti , F , Onofrj , M , Lugaresi , A , Terzi , M , Grammond , P , Grand’Maison , F , Yamout , B , Prat , A , Girard , M , Duquette , P , Boz , C , Trojano , M , McCombe , P , Slee , M , Lechner-Scott , J , Turkoglu , R , Sola , P , Ferraro , D , Granella , F , Prevost , J , Maimone , D , Skibina , O , Buzzard , K , Van Der Walt , A , Van Wijmeersch , B , Csepany , T , Spitaleri , D , Vucic , S , Casey , R , Debouverie , M , Edan , G , Ciron , J , Ruet , A , Sellebjerg , F T , Soerensen , P S , Jensen , M B , Frederiksen , J L , Bramow , S , Mathiesen , H K , Schreiber , K I , Magyari , M & Danish Multiple Sclerosis Registry, OFSEP and the MSBase Investigators 2021 , ’ Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis : A Subgroup Analysis From Three International Cohorts ’ , CNS Drugs , Vol. 35 , Pp. 1217–1232 . http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1322766594&authtype=sso&custid=ns315887.